Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janina Beha

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen|August 18, 2021
[The molecular tumor board]Pavlos Missios, Janina Beha, Michael Bitzer, et al.
NPJ Precision Oncology|April 2, 2025
Systematic review and meta-analysis of molecular tumor board data on clinical effectiveness and evaluation gapsBeryl Primrose Gladstone, Janina Beha, Arisa Hakariya, et al.
Bioinformatics (Oxford, England)|December 13, 2019
ClinVAP: a reporting strategy from variants to therapeutic optionsBilge Sürün, Charlotta P I Schärfe, Mathew R Divine, et al.
Journal of Personalized Medicine|December 27, 2024
Standardized Response Assessment in Patients with Advanced Cholangiocarcinoma Treated with Personalized TherapyStephan Ursprung, Wolfgang Thaiss, Janina Beha, et al.
Frontiers in Oncology|April 22, 2025
Case Report: FGFR2 inhibitor resistance via <i>PIK3CA</i> and <i>CDKN2A/B</i> in an intrahepatic cholangiocarcinoma patient with <i>FGFR2-SH3GLB1</i> fusionNadja Ballin, Alexander Ott, Olga Seibel-Kelemen, et al.
JCO Precision Oncology|September 14, 2020
Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment OptionsMichael Bitzer, Leonie Ostermann, Marius Horger, et al.
NPJ Precision Oncology|September 4, 2021
Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinomaMichael Bitzer, Stephan Spahn, Sepideh Babaei, et al.
Neuro-Oncology Advances|March 14, 2023
Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous systemMirjam Renovanz, Sylvia C Kurz, Johannes Rieger, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen|August 18, 2021
[The molecular tumor board]Pavlos Missios, Janina Beha, Michael Bitzer, et al.
NPJ Precision Oncology|April 2, 2025
Systematic review and meta-analysis of molecular tumor board data on clinical effectiveness and evaluation gapsBeryl Primrose Gladstone, Janina Beha, Arisa Hakariya, et al.
Bioinformatics (Oxford, England)|December 13, 2019
ClinVAP: a reporting strategy from variants to therapeutic optionsBilge Sürün, Charlotta P I Schärfe, Mathew R Divine, et al.
Journal of Personalized Medicine|December 27, 2024
Standardized Response Assessment in Patients with Advanced Cholangiocarcinoma Treated with Personalized TherapyStephan Ursprung, Wolfgang Thaiss, Janina Beha, et al.
Frontiers in Oncology|April 22, 2025
Case Report: FGFR2 inhibitor resistance via <i>PIK3CA</i> and <i>CDKN2A/B</i> in an intrahepatic cholangiocarcinoma patient with <i>FGFR2-SH3GLB1</i> fusionNadja Ballin, Alexander Ott, Olga Seibel-Kelemen, et al.
JCO Precision Oncology|September 14, 2020
Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment OptionsMichael Bitzer, Leonie Ostermann, Marius Horger, et al.
NPJ Precision Oncology|September 4, 2021
Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinomaMichael Bitzer, Stephan Spahn, Sepideh Babaei, et al.
Neuro-Oncology Advances|March 14, 2023
Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous systemMirjam Renovanz, Sylvia C Kurz, Johannes Rieger, et al.
Pageof 1